Feng L Z, Peng Z B, Wang D Y, Yang P, Yang J, Zhang Y Y, Chen J, Jiang S Q, Xu L L, Kang M, Chen T, Zheng Y M, Zheng J D, Qin Y, Zhao M J, Tan Y Y, Li Z J, Feng Z J
Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Nov 6;52(11):1101-1114. doi: 10.3760/cma.j.issn.0253-9624.2018.11.003.
Seasonal influenza vaccination is the most effective way to prevent influenza virus infection and complications from infection. Currently, China has licensed trivalent inactivated influenza vaccine (IIV3) and quadrivalent inactivated influenza vaccine (IIV4), including split-virus influenza vaccine and subunit vaccine. Except for a few major cities, influenza vaccine is a category Ⅱ vaccine, which means influenza vaccination is voluntary, and recipients must pay for it. To strengthen the technical guidance for prevention and control of influenza and operational research on influenza vaccination in China, the National Immunization Advisory Committee (NIAC) Influenza Vaccine Technical Working Group (TWG), updated the 2014 technical guidelines and compiled the "Technical guidelines for seasonal influenza vaccination in China (2018-2019)" . The main updates in this version include: epidemiology, disease burden, types of influenza vaccines, northern hemisphere influenza vaccination composition for the 2018-2019 season, IIV3 and IIV4 immune response, durability of immunity, immunogenicity, vaccine efficacy, effectiveness, safety, cost-effectiveness and cost-benefit. The influenza vaccine TWG provided the recommendations for influenza vaccination for the 2018-2019 influenza season based on existing scientific evidence. The recommendations described in this report include the following: Points of Vaccination clinics (PoVs) should provide influenza vaccination to all persons aged 6 months and above who are willing to be vaccinated and do not have contraindications. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available. To decrease the risk of severe infections and complications due to influenza virus infection among high risk groups, the recommendations prioritize seasonal influenza vaccination for children aged 6-59 months, adults ≥60 years of age, persons with specific chronic diseases, healthcare workers, the family members and caregivers of infants <6 months of age, and pregnant women or women who plan to become pregnant during the influenza season. Children aged 6 months through 8 years require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection. If they were vaccinated in 2017-2018 influenza season or a prior season, 1 dose is recommended. People more than 8 years old require 1 dose of influenza vaccine. It is recommended that people receive their influenza vaccination by the end of October. Influenza vaccination should be offered as soon as the vaccination is available. For the people unable to be vaccinated before the end of October, influenza vaccination will continue to be offered for the whole season. Influenza vaccine is also recommended for use in pregnant women during any trimester. These guidelines are intended for use by staff members of the Centers for Disease Control and Prevention at all levels who work on influenza control and prevention, PoVs staff members, healthcare workers from the departments of pediatrics, internal medicine, and infectious diseases, and staff members of maternity and child care institutions at all levels.
季节性流感疫苗接种是预防流感病毒感染及感染并发症的最有效方法。目前,中国已批准三价灭活流感疫苗(IIV3)和四价灭活流感疫苗(IIV4),包括裂解流感疫苗和亚单位疫苗。除少数大城市外,流感疫苗属于二类疫苗,这意味着流感疫苗接种是自愿的,受种者需自费。为加强中国流感防控技术指导及流感疫苗接种工作研究,国家免疫规划专家咨询委员会(NIAC)流感疫苗技术工作组(TWG)更新了2014年技术指南,编写了《中国季节性流感疫苗接种技术指南(2018—2019)》。本版主要更新内容包括:流行病学、疾病负担、流感疫苗种类、2018—2019年北半球流感疫苗接种组分、IIV3和IIV4的免疫反应、免疫持久性、免疫原性、疫苗效力、效果、安全性、成本效益和成本收益。流感疫苗TWG根据现有科学证据给出了2018—2019年流感季流感疫苗接种建议。本报告中的建议包括以下内容:接种门诊应向所有愿意接种且无禁忌证的6月龄及以上人群提供流感疫苗接种服务。对于有多种已获许可、推荐且适用产品的人群,不特别推荐某一种流感疫苗产品优于另一种。为降低高危人群因流感病毒感染导致严重感染和并发症的风险,建议优先为6—59月龄儿童、≥60岁成人、患有特定慢性病的人群、医护人员、6月龄以下婴儿的家庭成员和照护者,以及流感季期间的孕妇或计划怀孕的女性接种季节性流感疫苗。6月龄至8岁儿童在首次接种流感疫苗的季节需要接种2剂,间隔至少4周以获得最佳保护。若其在2017—2018年流感季或之前的季节已接种过,建议接种1剂。8岁以上人群需要接种1剂流感疫苗。建议人们在10月底前接种流感疫苗。只要有流感疫苗,应尽早提供接种服务。对于10月底前无法接种的人群,整个流感季均可继续提供接种服务。也建议孕妇在任何孕周接种流感疫苗。本指南供各级从事流感防控工作的疾病预防控制中心工作人员、接种门诊工作人员、儿科、内科和感染科医护人员以及各级妇幼保健机构工作人员使用。